Pacific Edge (NZE:PEB, ASX:PEB) said its product Cxbladder Triage has been included by the American Urological Association as the standard of care in an amendment to its clinical guideline for microhematuria patients, according to a Friday filing with the Australian and New Zealand bourses.

The guideline mentions the product as the only urine-based biomarker test that has "Grade A" evidence from a randomized controlled trial in support of this recommendation, the filing said.

Company shares rose 5% in recent Monday trade in New Zealand and jumped almost 22% in Australia.